
    
      CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal
      antibody that is being developed as a similar biological medicinal product to Humira. The
      purpose of this study is to demonstrate similar efficacy and safety of CT-P17 and Humira in
      patients with moderate to severe rheumatoid arthritis when co-administered with methotrexate.
    
  